Inhibition of formation of amyloid b-protein fibrils using cactus mucilage extracts

Patent metadata

Field	Value
Publication number	US-2019328811-A1
Application number	US-201916502850-A
Country	US
Kind code	A1
Filing date	Jul 3, 2019
Priority date	Sep 16, 2016
Publication date	Oct 31, 2019
Grant date	—

Abstract

A method of slowing progression of an amyloid disease by administration of cactus mucilage extract from Opuntia ficus-indicia is presented. Both gelling and non-gelling cactus mucilage extracts were found to induce changes in the secondary structures of the amyloid beta peptides thus interfering with formation of Aβ fibrils and aggregation of Aβ fibrils into plaques.

First claim

What is claimed is:

1 ] A method of inhibiting formation of amyloid beta (Aβ) plaques in a patient suffering from an amyloid disease comprising:
obtaining plant mucilage extract from Opuntia ficus -indica wherein the plant mucilage extract is gelling extract, non-gelling extract or a combination thereof;
wherein the gelling extract is formed by steps comprising:
obtaining cactus pads;
dicing and boiling the cactus pads;
liquidizing the cactus pads and adding a base to neutralize the liquidized cactus pads;
centrifuging the liquidized cactus pads into a liquid fraction and a solid precipitate;
collecting the solid precipitate;
adding sodium hexametaphosphate to the solid precipitate and mixing;
filtering the solid precipitate;
resuspending the solid precipitate in deionized water to form a suspension;
lowering the pH of the suspension;
precipitating a mucilage precipitate from the suspension;
resuspending the mucilage precipitate with water and adjusting the pH until the mucilage precipitate dissolves; and
filtering the dissolved mucilage precipitate to form the gelling extract;

wherein the non-gelling extract is formed by steps comprising:
obtaining cactus pads;
dicing and boiling the cactus pads;
liquidizing the cactus pads and adding a base to neutralize the liquidized cactus pads;
centrifuging the liquidized cactus pads into a liquid fraction and a solid precipitate;
collecting the liquid fraction;
adding sodium chloride to the liquid fraction and mixing;
filtering the liquid fraction to form a filtrate;
adding acetone or isopropanol to the filtrate to form a mucilage precipitate;
washing the precipitate; and
drying the precipitate to form the non-gelling extract; and

administering a therapeutically effective amount of the plant mucilage extract to the patient;
wherein administration of the plant mucilage disrupts aggregation of amyloid beta (Aβ) fibrils into plaques.

2 ] The method of claim 1 , further comprising combining the plant mucilage extract with a pharmaceutically acceptable carrier prior to administration to the patient.

3 ] The method of claim 1 , wherein the plant mucilage extract is the combination of the gelling extract and the non-gelling extract.

4 ] The method of claim 1 , wherein the amyloid disease is Alzheimer's disease or Parkinson's disease.

5 ] The method of claim 1 , wherein the plant mucilage extract is administered to a central nervous system of the patient.

6 ] The method of claim 5 , wherein the plant mucilage extract is administered to the central nervous system of the patient through a pump implanted in the patient.

7 ] A method of slowing progression of Alzheimer's disease in a patient suffering therefrom comprising:
obtaining plant mucilage extract from Opuntia ficus -indica wherein the plant mucilage extract is gelling extract, non-gelling extract or a combination thereof; wherein the gelling extract is formed by steps comprising:
obtaining cactus pads;
dicing and boiling the cactus pads;
liquidizing the cactus pads and adding a base to neutralize the liquidized cactus pads;
centrifuging the liquidized cactus pads into a liquid fraction and a solid precipitate;
collecting the solid precipitate;
adding sodium hexametaphosphate to the solid precipitate and mixing;
filtering the solid precipitate;
resuspending the solid precipitate in deionized water to form a suspension;
lowering the pH of the suspension;
precipitating a mucilage precipitate from the suspension;
resuspending the mucilage precipitate with water and adjusting the pH until the mucilage precipitate dissolves; and
filtering the dissolved mucilage precipitate to form the gelling extract;
wherein the non-gelling extract is formed by steps comprising:
obtaining cactus pads;
dicing and boiling the cactus pads;
liquidizing the cactus pads and adding a base to neutralize the liquidized cactus pads;
centrifuging the liquidized cactus pads into a liquid fraction and a solid precipitate;
collecting the liquid fraction;
adding sodium chloride to the liquid fraction and mixing;
filtering the liquid fraction to form a filtrate;
adding acetone or isopropanol to the filtrate to form a mucilage precipitate;
washing the precipitate; and
drying the precipitate to form the non-gelling extract; and
administering a therapeutically effective amount of the plant mucilage extract to the patient; wherein administration of the plant mucilage extract disrupts formation of amyloid beta (Aβ) fibrils and aggregation of the Aβ fibrils into plaques to slow the progression of Alzheimer's disease in the patient.

8 ] The method of claim 7 , further comprising combining the plant mucilage extract with a pharmaceutically acceptable carrier prior to administration to the patient.

9 ] The method of claim 7 , wherein the plant mucilage extract is administered to a central nervous system of the patient.

10 ] The method of claim 9 , wherein the plant mucilage extract is administered to the central nervous system of the patient through a pump implanted in the patient.

11 ] The method of claim 7 , wherein the plant mucilage extract is the combination of the gelling extract and the non-gelling extract.

Assignees

• Alcantar Norma A
• Morgan David
• Veisi Zeinab
• Breydo Leonid
• Uversky Vladimir N
• Toomey Ryan G
• Peng Tunan
• Lobbens Eva Stephanie
• Univ South Florida

Inventors

• Alcantar Norma A
• Morgan David
• Veisi Zeinab
• Breydo Leonid
• Uversky Vladimir N
• Toomey Ryan G
• Peng Tunan
• Lobbens Eva Stephanie

Classifications

• A61M5/14276

  specially adapted for implantation · CPC title

• A61K36/33 Primary

  Cactaceae (Cactus family), e.g. pricklypear or Cereus · CPC title

• A61K2236/00

  Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine · CPC title

• A61P25/28 Primary

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K2236/15

  involving mechanical treatment, e.g. chopping up, cutting or grinding · CPC title